Avails Medical
Avails Medical is a clinical diagnostics company developing electronic biosensor systems for rapid antimicrobial susceptibility testing. Its FDA-cleared eQUANT System and pipeline eAST System serve hospital clinical microbiology laboratories, accelerating AST results from positive blood cultures.
- Company typePrivate
- Founded2013
- HeadquartersMenlo Park, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Avails Medical does
Avails Medical is a privately held clinical diagnostics company founded in 2013 and headquartered in Menlo Park, California, that develops electronic biosensor-based systems for rapid antimicrobial susceptibility testing (AST). The company targets hospital clinical microbiology laboratories serving patients with bloodstream infections and sepsis, addressing the 24-96 hour turnaround times of conventional AST workflows that contribute to sepsis mortality (over 50 million diagnosed annually worldwide with ~20% mortality) and antimicrobial resistance through delayed targeted antibiotic therapy.
The company's FDA-cleared eQUANT™ System uses potentiometric sensing of oxidation-reduction potential (ORP) changes from pathogen metabolism to generate a standardized 0.5 McFarland equivalent suspension (eMcFarland) directly from positive blood cultures in approximately 70 minutes, eliminating the overnight subculture step and reducing routine AST turnaround times by up to 24 hours. The system is cleared for 89 drug-bug combinations for gram-negative bacteria and demonstrated 95.0% overall categorical agreement with gold-standard methods across 2,679 AST result pairs in multicenter evaluation. The pipeline eAST™ System is a multi-slot rapid AST platform designed to deliver susceptibility results directly from positive blood cultures in approximately 5 hours, enabling potential same-day reporting. The company holds six issued U.S. patents and registered trademarks for the eQUANT, eAST, eTUBE, eLID, and ePANEL product lines.
Avails employs an enterprise field sales model targeting large hospital systems and academic medical centers, with its first U.S. commercial agreement signed in August 2025 with the flagship hospital of a six-hospital academic medical center system. Revenue mechanics combine capital sales of the eQUANT instrument with recurring consumables revenue from proprietary eTUBE disposable cuvettes required for each test run. The company has built out a commercial leadership team in 2024 including a VP of Sales (formerly T2 Biosystems), VP of Marketing (formerly bioMérieux/BioFire), VP of Finance (formerly Guardant Health/Deepcell), and EVP of Commercialization (formerly Karius/GenePOC). To date the company has been primarily funded through non-dilutive CARB-X grants (~$9.6 million received, with potential total of up to $14.7 million upon milestones) and earlier seed-stage rounds totaling approximately $7.4 million.
Avails Medical firmographics
Firmographics- Name
- Avails Medical
- Legal name
- Avails Medical, Inc.
- Website
- https://availsmedical.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Avails Medical is a clinical diagnostics company developing electronic biosensor systems for rapid antimicrobial susceptibility testing. Its FDA-cleared eQUANT System and pipeline eAST System serve hospital clinical microbiology laboratories, accelerating AST results from positive blood cultures.
- Ownership category
- akta.pro rank
Avails Medical industry classification
Industry- Product category
- Clinical Microbiology / Rapid Antimicrobial Susceptibility Testing (AST) Diagnostics
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)
- akta.pro secondary industries
- Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD)
Keywords
Where Avails Medical is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Avails Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- eQUANT System Hardware Sales: Sale of the eQUANT instrument and consumables (eTUBE Disposables, workflow trays). The company signed its first commercial customer in August 2025, indicating early commercialization phase. System includes single module instrument with proprietary disposable components requiring ongoing purchase.
- Consumables and Reagents: Ongoing revenue from proprietary consumables including eTUBE Disposables and reagent tubes required for each test run on the eQUANT System.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based enterprise pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Avails Medical product offering
Product offeringCore offering
Avails Medical develops and sells the FDA-cleared eQUANT™ System, a bench-top instrument that uses proprietary electronic biosensor technology to generate a standardized 0.5 McFarland equivalent bacterial suspension directly from positive blood cultures in approximately 70 minutes, accelerating downstream disk diffusion antimicrobial susceptibility testing (AST) by up to 24 hours for hospital clinical microbiology laboratories. The company is also developing the eAST™ rapid AST system (multi-slot, ~5-hour results) and sells proprietary eTUBE disposable consumables used with the eQUANT System.
Product overview
Avails Medical offers a platform of rapid antibiotic susceptibility testing (AST) diagnostic products. The flagship FDA-cleared eQUANT™ System is an automated bench-top instrument that generates standardized bacterial inoculum (eMcFarland) directly from positive blood cultures for downstream disk diffusion AST, accelerating results by up to 24 hours. The eAST™ System (under development) is a next-generation multi-slot rapid AST platform designed to deliver same-day susceptibility results directly from positive blood cultures in approximately five hours. Both products leverage the company's proprietary electronic biosensor technology that detects real-time oxidation-reduction potential changes from pathogen metabolism, eliminating traditional manual culturing steps. The products are designed for clinical microbiology laboratories serving hospitals of all sizes.
Differentiator
Problem solved
Functional benefit
Brands
- eQUANT: FDA-cleared system that generates a 0.5 McFarland equivalent directly from positive blood cultures in approximately 70 minutes, enabling AST results up to 24 hours faster.
- eAST
- eTUBE
Products and services
- eQUANT™ System FDA-cleared automated bench-top instrument that uses potentiometric sensing of oxidation-reduction potential (ORP) changes from pathogen metabolism to generate a standardized 0.5 McFarland equivalent suspension (eMcFarland) directly from positive blood cultures in approximately 70 minutes, for use in downstream disk diffusion antimicrobial susceptibility testing (AST) by hospital clinical microbiology laboratories.
- eAST™ System Multi-slot rapid antibiotic susceptibility testing (AST) platform under development designed to deliver AST results directly from positive blood cultures in approximately five hours, using the company's electronic biosensor technology to measure real-time redox changes from pathogen metabolism for same-day susceptibility reporting in clinical microbiology laboratories.
- eTUBE™ Cuvette Proprietary disposable reagent tube (cuvette) used with the eQUANT System as part of its consumables workflow, enabling standardized bacterial suspension preparation for downstream disk diffusion AST. Sold as a recurring-use consumable to eQUANT System customers.
Quantifiable outcome
- Reduces AST turnaround time by up to 24 hours for gram-negative organisms from positive blood cultures
- +4 more outcomes
Companies that use Avails Medical
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Avails Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Avails Medical partnerships and signals
Strategic signalScale indicators4 records
Recent moves7 records
Expansion highlights6 records
Avails Medical competitors and assessment
Company assessmentDirect peers
- T2 Biosystems: T2 Biosystems develops rapid diagnostics for sepsis and bloodstream infections, including the T2Bacteria and T2Candida panels plus T2Resistance — directly comparable to Avails' mission of accelerating AST directly from positive blood cultures and competing for the same hospital microbiology budget.
- Accelerate Diagnostics: Accelerate Diagnostics offers the Accelerate Pheno system, which delivers rapid identification and AST directly from positive blood cultures in hours — the closest direct competitor to Avails' eAST product and targeting the same sepsis/AST clinical workflow.
Broad incumbents
- bioMérieux: bioMérieux is the dominant incumbent in clinical microbiology with the VITEK 2 AST system and BioFire bloodstream infection panels, serving as the entrenched competitor Avails must displace in hospital microbiology labs.
- Beckman Coulter (Danaher): Beckman Coulter's MicroScan system is one of the most widely deployed AST platforms in U.S. hospital microbiology labs, representing both a benchmark incumbent and a potential channel/integration partner for Avails' automation.
- Becton Dickinson (BD): BD's Phoenix M50 AST system and BD MAX molecular platform are entrenched in hospital microbiology workflows, making BD a key incumbent competitor and a likely strategic acquirer for differentiated rapid-AST technologies.
Emerging players
- Selux Diagnostics: Selux Diagnostics is developing rapid phenotypic AST platforms targeting the same bloodstream infection workflow as Avails' eAST, making it a comparable emerging competitor in the next-generation rapid-AST category.
- Qvella: Qvella is developing rapid sample-to-result diagnostics for bloodstream infections, with technology aimed at collapsing the time from positive blood culture to actionable ID/AST — overlapping with Avails' sepsis-focused workflow thesis.
Others
- Copan Diagnostics: Copan Diagnostics specializes in automated specimen processing and liquid-handling microbiology platforms (e.g., WASP), making it an adjacent player in laboratory sample-prep automation relevant to Avails' eQUANT/eTUBE consumables model.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Avails Medical social profiles
Digital presenceAvails Medical compliance and trust
Trust signalCompliance1 record
Avails Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Avails Medical leadership team
Management profileNumber of profiles
Profiles11 records
Avails Medical funding detail
Funding detailFunding overview
Funding rounds7 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Avails Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Avails Medical
What does Avails Medical do?
Avails Medical develops and sells the FDA-cleared eQUANT™ System, a bench-top instrument that uses proprietary electronic biosensor technology to generate a standardized 0.5 McFarland equivalent bacterial suspension directly from positive blood cultures in approximately 70 minutes, accelerating downstream disk diffusion antimicrobial susceptibility testing (AST) by up to 24 hours for hospital clinical microbiology laboratories. The company is also developing the eAST™ rapid AST system (multi-slot, ~5-hour results) and sells proprietary eTUBE disposable consumables used with the eQUANT System.
Is Avails Medical a public or private company?
Avails Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Avails Medical founded?
Avails Medical was founded in 2013. It employs 11 to 50 people.
Where is Avails Medical based?
Avails Medical is headquartered in Menlo Park, United States, in the North America region.
How does Avails Medical make money?
Two revenue lines are on record. eQUANT System Hardware Sales are the primary driver. The others are consumables and Reagents.
Who are Avails Medical's main competitors?
Direct peers on record are T2 Biosystems and Accelerate Diagnostics. Broad incumbents are bioMérieux, Beckman Coulter (Danaher) and Becton Dickinson (BD). Emerging players are Selux Diagnostics and Qvella. Copan Diagnostics is listed as an others.
Does Avails Medical have an API?
No public API is recorded for Avails Medical.
What industry is Avails Medical in?
Avails Medical's product category is Clinical Microbiology / Rapid Antimicrobial Susceptibility Testing (AST) Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 334516 and its SIC code is 3826.